-
Uncategorized3 weeks ago
Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio
Through its DualityBio deal, Roche’s Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance.
-
Uncategorized3 weeks ago
AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis win
Even without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for Dupixent in eosinophilic esophagitis.
-
Uncategorized3 weeks ago
Multispecifics are transforming the CDMO development architecture
Manufacturers are being pushed beyond mAb‑era platforms into a new design model built around molecular engineering, complex analytics and amplified upstream and downstream processing.
-
Uncategorized3 weeks ago
CAR T for autoimmune disease benefits from oncology’s lessons—and will deliver its own
Thanks in part to the revolution cell therapy brought to treating blood cancers, the modality is now showing promise in some autoimmune applications. This expansion is...
-
Uncategorized3 weeks ago
Megascale microbiome analysis with DartUniFrac
Nature Biotechnology, Published online: 28 August 2026; doi:10.1038/s41587-026-03260-8 DartUniFrac enables scalable microbiome analysis of up to millions of samples and taxa.
-
Uncategorized3 weeks ago
Genetic Toolkit Isolates Neuron Types in Drosophila Brain
The fruit fly brain is small enough to map in exquisite detail, but that does not mean its signaling systems are simple. A single neuromodulator can...
-
Uncategorized3 weeks ago
UCSF QBI Awarded $46M to Translate Landmark Autism Map Into Precision Therapies
UCSF QBI Awarded $46M to Translate Landmark Autism Map Into Precision Therapies
-
Uncategorized3 weeks ago
Michael Polansky has a new, skin-focused biotech. Don’t call it a drug company.
Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious about steering clear of road bumps that slow biotechs.
-
Uncategorized3 weeks ago
RevMed could become ‘next oncology titan’ with Rasonque nod
A future expansion of Rasonque into first-line pancreatic ductal adenocarcinoma could set Revolution Medicines up to hit $2.3 billion in sales by 2028, according to Truist...
-
Uncategorized3 weeks ago
AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis
AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received...
Ensuring safety and accountability in China’s biomedical translation system
Blood centers can help biopharma scale cell and gene therapies
Psychedelics at FDA, Mike Davis’ CDER and translating tRNAs — a BioCentury podcast
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
